Intracranial antitumor efficacy of combination treatment with encorafenib plus binimetinib in BRAF V600E-mutated anaplastic thyroid carcinoma

IF 1.8 4区医学 Q2 OTORHINOLARYNGOLOGY

Auris Nasus Larynx Pub Date : 2026-02-01 Epub Date: 2025-12-04 DOI:10.1016/j.anl.2025.11.007

Ryutaro Onaga , Tomohiro Enokida , Toshifumi Tomioka , Shingo Sakashita , Masanobu Sato , Nobukazu Tanaka , Yuta Hoshi , Takuma Kishida , Ryo Kuboki , Takao Fujisawa , Susumu Okano , Kazuto Matsuura , Makoto Tahara

{"title":"Intracranial antitumor efficacy of combination treatment with encorafenib plus binimetinib in BRAF V600E-mutated anaplastic thyroid carcinoma","authors":"Ryutaro Onaga , Tomohiro Enokida , Toshifumi Tomioka , Shingo Sakashita , Masanobu Sato , Nobukazu Tanaka , Yuta Hoshi , Takuma Kishida , Ryo Kuboki , Takao Fujisawa , Susumu Okano , Kazuto Matsuura , Makoto Tahara","doi":"10.1016/j.anl.2025.11.007","DOIUrl":null,"url":null,"abstract":"<div><div>The intracranial antitumor efficacy of combination therapy with BRAF and MEK inhibitors in <em>BRAF</em>-mutated thyroid cancer has not been reported. Here, we describe a case of anaplastic thyroid cancer harboring <em>BRAF</em> V600E mutation with brain metastases which was treated with encorafenib plus binimetinib. The patient was initially diagnosed with T4bN1bM1 and experienced disease progression following surgery and lenvatinib treatment. Encorafenib plus binimetinib was initiated as second-line treatment seven months after the surgery. After achieving sustained disease stabilization, a solitary asymptomatic brain metastasis was detected following a three-week interruption due to COVID-19 infection. The lesion shrank after only two weeks of resumed encorafenib plus binimetinib, and additional stereotactic radiosurgery was performed without significant adverse events. This case suggests that the combination of BRAF and MEK inhibitors may be a viable treatment option for brain metastasis in <em>BRAF</em>-mutated thyroid cancer, despite general prioritization of local treatments. In addition, encorafenib plus binimetinib treatment may suppress the growth of microscopic metastasis. This possibility is supported by reliable evidence for the use of BRAF plus MEK inhibitor for brain metastasis from <em>BRAF</em>-mutated malignant melanoma. We conclude that encorafenib plus binimetinib treatment for brain metastasis from <em>BRAF</em>-mutated thyroid cancer is a safe and effective treatment choice.</div></div>","PeriodicalId":55627,"journal":{"name":"Auris Nasus Larynx","volume":"53 1","pages":"Pages 7-12"},"PeriodicalIF":1.8000,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Auris Nasus Larynx","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0385814625001737","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/12/4 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The intracranial antitumor efficacy of combination therapy with BRAF and MEK inhibitors in BRAF-mutated thyroid cancer has not been reported. Here, we describe a case of anaplastic thyroid cancer harboring BRAF V600E mutation with brain metastases which was treated with encorafenib plus binimetinib. The patient was initially diagnosed with T4bN1bM1 and experienced disease progression following surgery and lenvatinib treatment. Encorafenib plus binimetinib was initiated as second-line treatment seven months after the surgery. After achieving sustained disease stabilization, a solitary asymptomatic brain metastasis was detected following a three-week interruption due to COVID-19 infection. The lesion shrank after only two weeks of resumed encorafenib plus binimetinib, and additional stereotactic radiosurgery was performed without significant adverse events. This case suggests that the combination of BRAF and MEK inhibitors may be a viable treatment option for brain metastasis in BRAF-mutated thyroid cancer, despite general prioritization of local treatments. In addition, encorafenib plus binimetinib treatment may suppress the growth of microscopic metastasis. This possibility is supported by reliable evidence for the use of BRAF plus MEK inhibitor for brain metastasis from BRAF-mutated malignant melanoma. We conclude that encorafenib plus binimetinib treatment for brain metastasis from BRAF-mutated thyroid cancer is a safe and effective treatment choice.

查看原文本刊更多论文

恩可非尼联合比尼美替尼治疗BRAF v600e突变间变性甲状腺癌的颅内抗肿瘤疗效

BRAF和MEK抑制剂联合治疗BRAF突变甲状腺癌的颅内抗肿瘤疗效尚未报道。在这里，我们描述了一个携带BRAF V600E突变的间变性甲状腺癌伴脑转移的病例，用恩可非尼加比尼替尼治疗。患者最初被诊断为T4bN1bM1，并在手术和lenvatinib治疗后出现疾病进展。Encorafenib + binimetinib在手术后7个月开始作为二线治疗。在实现持续的疾病稳定后，由于COVID-19感染而中断三周后，发现了一个孤立的无症状脑转移。恢复恩可非尼加比尼美替尼治疗仅两周后，病变缩小，并进行了额外的立体定向放射手术，没有明显的不良事件。该病例提示，BRAF和MEK抑制剂联合治疗BRAF突变甲状腺癌脑转移可能是一种可行的治疗选择，尽管局部治疗通常优先。此外，恩可非尼联合比尼美替尼治疗可能抑制显微转移的生长。BRAF + MEK抑制剂用于BRAF突变的恶性黑色素瘤脑转移的可靠证据支持了这种可能性。我们的结论是，恩可非尼联合比尼美替尼治疗braf突变甲状腺癌脑转移是一种安全有效的治疗选择。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Auris Nasus Larynx 医学-耳鼻喉科学

CiteScore

3.40

自引率

5.90%

发文量

169

审稿时长

30 days

期刊介绍： The international journal Auris Nasus Larynx provides the opportunity for rapid, carefully reviewed publications concerning the fundamental and clinical aspects of otorhinolaryngology and related fields. This includes otology, neurotology, bronchoesophagology, laryngology, rhinology, allergology, head and neck medicine and oncologic surgery, maxillofacial and plastic surgery, audiology, speech science. Original papers, short communications and original case reports can be submitted. Reviews on recent developments are invited regularly and Letters to the Editor commenting on papers or any aspect of Auris Nasus Larynx are welcomed. Founded in 1973 and previously published by the Society for Promotion of International Otorhinolaryngology, the journal is now the official English-language journal of the Oto-Rhino-Laryngological Society of Japan, Inc. The aim of its new international Editorial Board is to make Auris Nasus Larynx an international forum for high quality research and clinical sciences.